{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:08:50Z","timestamp":1774285730377,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Science and Technology Council, Taiwan","award":["NSTC112-2320-B110-003"],"award-info":[{"award-number":["NSTC112-2320-B110-003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10495-023-01918-1","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T22:01:21Z","timestamp":1702072881000},"page":"503-520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression"],"prefix":"10.1007","volume":"29","author":[{"given":"Jing-Ting","family":"Chiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Sen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"1918_CR1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s13346-022-01189-4","volume":"13","author":"A Dozzo","year":"2023","unstructured":"Dozzo A, Galvin A, Shin JW, Scalia S, O\u2019Driscoll CM, Ryan KB (2023) Modelling acute myeloid leukemia (AML): what\u2019s new? A transition from the classical to the modern. Drug Deliv Transl Res 13:2110\u20132141","journal-title":"Drug Deliv Transl Res"},{"key":"1918_CR2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.599933","volume":"10","author":"X Roussel","year":"2020","unstructured":"Roussel X, Daguindau E, Berceanu A, Desbrosses Y, Warda W, Neto da Rocha M, Trad R, Deconinck E, Deschamps M, Ferrand C (2020) Acute myeloid leukemia: from biology to clinical practices through development and pre-clinical therapeutics. Front Oncol 10:599933","journal-title":"Front Oncol"},{"key":"1918_CR3","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/bloodadvances.2019001245","volume":"4","author":"D Pan","year":"2020","unstructured":"Pan D, Rampal R, Mascarenhas J (2020) Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Blood Adv 4:970\u2013982","journal-title":"Blood Adv"},{"key":"1918_CR4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F (2021) Acute myeloid leukemia: current progress and future directions. Blood Cancer J 11:41","journal-title":"Blood Cancer J"},{"key":"1918_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ijc.30420","volume":"140","author":"JN Poynter","year":"2017","unstructured":"Poynter JN, Richardson M, Roesler M, Blair CK, Hirsch B, Nguyen P, Cioc A, Cerhan JR, Warlick E (2017) Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. Int J Cancer 140:23\u201333","journal-title":"Int J Cancer"},{"key":"1918_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2017.179","volume":"25","author":"H Kalkavan","year":"2018","unstructured":"Kalkavan H, Green DR (2018) MOMP, cell suicide as a BCL-2 family business. Cell Death Differ 25:46\u201355","journal-title":"Cell Death Differ"},{"key":"1918_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW (2018) BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25:65\u201380","journal-title":"Cell Death Differ"},{"key":"1918_CR8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A (2018) BCL-2 inhibition in AML: an unexpected bonus? Blood 132:1007\u20131012","journal-title":"Blood"},{"key":"1918_CR9","volume":"10","author":"Y Wei","year":"2020","unstructured":"Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, He X, Lu W, Zhao M (2020) Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol 10:584974","journal-title":"Front Oncol"},{"key":"1918_CR10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.tips.2020.09.004","volume":"41","author":"C Cerella","year":"2020","unstructured":"Cerella C, Dicato M, Diederich M (2020) BH3 mimetics in AML therapy: death and beyond? Trends Pharmacol Sci 41:793\u2013814","journal-title":"Trends Pharmacol Sci"},{"key":"1918_CR11","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1038\/sigtrans.2017.12","volume":"2","author":"DA Luedtke","year":"2017","unstructured":"Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y (2017) Inhibition of Mcl-1 enhances cell death induced by the bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther 2:17012","journal-title":"Signal Transduct Target Ther"},{"key":"1918_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115494","volume":"211","author":"JT Chiou","year":"2023","unstructured":"Chiou JT, Hsu CC, Hong YC, Lee YC, Chang LS (2023) Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells. Biochem Pharmacol 211:115494","journal-title":"Biochem Pharmacol"},{"key":"1918_CR13","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35:1873\u20131889","journal-title":"Leukemia"},{"key":"1918_CR14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood.2019000942","volume":"136","author":"AJ Menssen","year":"2020","unstructured":"Menssen AJ, Walter MJ (2020) Genetics of progression from MDS to secondary leukemia. Blood 136:50\u201360","journal-title":"Blood"},{"key":"1918_CR15","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","volume":"5","author":"PW Hollenbach","year":"2010","unstructured":"Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 5:e9001","journal-title":"PLoS ONE"},{"key":"1918_CR16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3892\/ijo.2012.1546","volume":"41","author":"DY Shin","year":"2012","unstructured":"Shin DY, Park YS, Yang K, Kim GY, Kim WJ, Han MH, Kang HS, Choi YH (2012) Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation. Int J Oncol 41:910\u2013918","journal-title":"Int J Oncol"},{"key":"1918_CR17","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","volume":"28","author":"JM Bogenberger","year":"2014","unstructured":"Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R (2014) BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28:1657\u20131665","journal-title":"Leukemia"},{"key":"1918_CR18","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, Solomon LR, Boghaert ER, Leverson JD, Phillips DC (2020) 5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res 26:3371\u20133383","journal-title":"Clin Cancer Res"},{"key":"1918_CR19","volume":"2021","author":"L Li","year":"2021","unstructured":"Li L, Liu W, Sun Q, Zhu H, Hong M, Qian S (2021) Decitabine downregulates TIGAR to induce apoptosis and autophagy in myeloid leukemia cells. Oxid Med Cell Longev 2021:8877460","journal-title":"Oxid Med Cell Longev"},{"key":"1918_CR20","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1038\/s41467-021-26258-z","volume":"12","author":"J Diesch","year":"2021","unstructured":"Diesch J, Le Pann\u00e9rer MM, Winkler R, Casquero R, Muhar M, van der Garde M, Maher M, Herr\u00e1ez CM, Bech-Serra JJ, Fellner M, Rathert P, Brooks N, Zamora L, Gentilella A, de la Torre C, Zuber J, G\u00f6tze KS, Buschbeck M (2021) Inhibition of CBP synergizes with the RNA-dependent mechanisms of azacitidine by limiting protein synthesis. Nat Commun 12:6060","journal-title":"Nat Commun"},{"key":"1918_CR21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3324\/haematol.2020.272609","volume":"107","author":"D Cojocari","year":"2022","unstructured":"Cojocari D, Smith BN, Purkal JJ, Arrate MP, Huska JD, Xiao Y, Gorska A, Hogdal LJ, Ramsey HE, Boghaert ER, Phillips DC, Savona MR (2022) Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica 107:825\u2013835","journal-title":"Haematologica"},{"key":"1918_CR22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","volume":"35","author":"X Gu","year":"2021","unstructured":"Gu X, Tohme R, Tomlinson B, Sakre N, Hasipek M, Durkin L, Schuerger C, Grabowski D, Zidan AM, Radivoyevitch T, Hong C, Carraway H, Hamilton B, Sobecks R, Patel B, Jha BK, Hsi ED, Maciejewski J, Saunthararajah Y (2021) Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia 35:1023\u20131036","journal-title":"Leukemia"},{"key":"1918_CR23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jha2.663","volume":"4","author":"IM Bouligny","year":"2023","unstructured":"Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR (2023) Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. EJHaem 4:381\u2013392","journal-title":"EJHaem"},{"key":"1918_CR24","doi-asserted-by":"crossref","first-page":"114544","DOI":"10.1016\/j.bcp.2021.114544","volume":"188","author":"JT Chiou","year":"2021","unstructured":"Chiou JT, Lee YC, Huang CH, Wang LJ, Shi YJ, Chang LS (2021) Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells. Biochem Pharmacol 188:114544","journal-title":"Biochem Pharmacol"},{"key":"1918_CR25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","volume":"16","author":"H Garg","year":"2016","unstructured":"Garg H, Suri P, Gupta JC, Talwar GP, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16:49","journal-title":"Cancer Cell Int"},{"key":"1918_CR26","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.1002\/jcp.30407","volume":"236","author":"JT Chiou","year":"2021","unstructured":"Chiou JT, Huang NC, Huang CH, Wang LJ, Lee YC, Shi YJ, Chang LS (2021) NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. J Cell Physiol 236:7356\u20137375","journal-title":"J Cell Physiol"},{"key":"1918_CR27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ijbiomac.2021.07.133","volume":"187","author":"JT Chiou","year":"2021","unstructured":"Chiou JT, Shi YJ, Lee YC, Wang LJ, Chen YJ, Chang LS (2021) Carboxyl group-modified \u03b1-lactalbumin induces TNF-\u03b1-mediated apoptosis in leukemia and breast cancer cells through the NOX4\/p38 MAPK\/PP2A axis. Int J Biol Macromol 187:513\u2013527","journal-title":"Int J Biol Macromol"},{"key":"1918_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.taap.2017.08.019","volume":"334","author":"CH Huang","year":"2017","unstructured":"Huang CH, Lee YC, Chen YJ, Wang LJ, Shi YJ, Chang LS (2017) Quinacrine induces the apoptosis of human leukemia U937 cells through FOXP3\/miR-183\/\u03b2-TrCP\/SP1 axis-mediated BAX upregulation. Toxicol Appl Pharmacol 334:35\u201346","journal-title":"Toxicol Appl Pharmacol"},{"key":"1918_CR29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-genet-102108-134850","volume":"43","author":"C Wang","year":"2009","unstructured":"Wang C, Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43:95\u2013118","journal-title":"Annu Rev Genet"},{"key":"1918_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11010-010-0683-3","volume":"350","author":"B Brodsk\u00e1","year":"2011","unstructured":"Brodsk\u00e1 B, Otev\u0159elov\u00e1 P, Holoubek A (2011) Decitabine-induced apoptosis is derived by puma and noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Mol Cell Biochem 350:71\u201380","journal-title":"Mol Cell Biochem"},{"key":"1918_CR31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/cancers14010248","volume":"14","author":"W Nakajima","year":"2022","unstructured":"Nakajima W, Miyazaki K, Sakaguchi M, Asano Y, Ishibashi M, Kurita T, Yamaguchi H, Takei H, Tanaka N (2022) Epigenetic priming with decitabine augments the therapeutic effect of cisplatin on triple-negative breast cancer cells through induction of proapoptotic factor NOXA. Cancers. 14:248","journal-title":"Cancers."},{"key":"1918_CR32","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nchembio.1590","volume":"10","author":"GE Winter","year":"2014","unstructured":"Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KVM, Gridling M, Chen D, Klampfl T, Kralovics R, Kubicek S, Fernandez-Capetillo O, Brummelkamp TR, Superti-Furga G (2014) The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Nat Chem Biol 10:768\u2013773","journal-title":"Nat Chem Biol"},{"key":"1918_CR33","doi-asserted-by":"crossref","first-page":"109978","DOI":"10.1016\/j.cbi.2022.109978","volume":"361","author":"JT Chiou","year":"2022","unstructured":"Chiou JT, Lee YC, Wang LJ, Chang LS (2022) BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells. Chem Biol Interact 361:109978","journal-title":"Chem Biol Interact"},{"key":"1918_CR34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-022-01329-0","volume":"14","author":"T Aumer","year":"2022","unstructured":"Aumer T, Gremmelmaier CB, Runtsch LS, Pforr JC, Ye\u015filta\u00e7 GN, Kaiser S, Traube FR (2022) Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line. Clin Epigenet 14:113","journal-title":"Clin Epigenet"},{"key":"1918_CR35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00277-005-0006-z","volume":"84","author":"A Gozzini","year":"2005","unstructured":"Gozzini A, Santini V (2005) Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol 84:54\u201360","journal-title":"Ann Hematol"},{"key":"1918_CR36","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1158\/1078-0432.CCR-13-1453","volume":"20","author":"TE Fandy","year":"2014","unstructured":"Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD (2014) Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res 20:1249\u20131258","journal-title":"Clin Cancer Res"},{"key":"1918_CR37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ceca.2017.01.007","volume":"63","author":"N Hempel","year":"2017","unstructured":"Hempel N, Trebak M (2017) Crosstalk between calcium and reactive oxygen species signaling in cancer. Cell Calcium 63:70\u201396","journal-title":"Cell Calcium"},{"key":"1918_CR38","first-page":"792639","volume":"2011","author":"Y Son","year":"2011","unstructured":"Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO (2011) Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J Signal Transduct 2011:792639","journal-title":"J Signal Transduct"},{"key":"1918_CR39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00160","volume":"8","author":"N Koundouros","year":"2018","unstructured":"Koundouros N, Poulogiannis G (2018) Phosphoinositide 3-Kinase\/Akt signaling and redox metabolism in cancer. Front Oncol 8:160","journal-title":"Front Oncol"},{"key":"1918_CR40","first-page":"2760","volume":"30","author":"LH Li","year":"1970","unstructured":"Li LH, Olin EJ, Buskirk HH, Reineke LM (1970) Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 30:2760\u20132769","journal-title":"Cancer Res"},{"key":"1918_CR41","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/onc.2009.62","volume":"28","author":"NH Nabilsi","year":"2009","unstructured":"Nabilsi NH, Broaddus RR, Loose DS (2009) DNA methylation inhibits p53-mediated survivin repression. Oncogene 28:2046\u20132050","journal-title":"Oncogene"},{"key":"1918_CR42","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41418-020-0503-6","volume":"27","author":"MD Haschka","year":"2020","unstructured":"Haschka MD, Karbon G, Soratroi C, O\u2019Neill KL, Luo X, Villunger A (2020) MARCH5-dependent degradation of MCL1\/NOXA complexes defines susceptibility to antimitotic drug treatment. Cell Death Differ 27:2297\u20132312","journal-title":"Cell Death Differ"},{"key":"1918_CR43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.113.204743","volume":"346","author":"DR Premkumar","year":"2013","unstructured":"Premkumar DR, Jane EP, Foster KA, Pollack IF (2013) Survivin inhibitor YM-155 sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther 346:201\u2013210","journal-title":"J Pharmacol Exp Ther"},{"key":"1918_CR44","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrg.2017.33","volume":"18","author":"X Wu","year":"2017","unstructured":"Wu X, Zhang Y (2017) TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet 18:517\u2013534","journal-title":"Nat Rev Genet"},{"key":"1918_CR45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.14740\/jh531","volume":"8","author":"J Alves","year":"2019","unstructured":"Alves J, Dexheimer GM, Reckzigel L, Goettert M, Biolchi V, Abujamra AL (2019) Changes in IDH2, TET2 and KDM2B gene expression after treatment with classic chemotherapeutic agents and decitabine in myelogenous leukemia cell lines. J Hematol 8:89\u2013101","journal-title":"J Hematol"},{"key":"1918_CR46","doi-asserted-by":"crossref","first-page":"114253","DOI":"10.1016\/j.bcp.2020.114253","volume":"182","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Kalpage HA, Edwards H, H\u00fcttemann M, Taub JW, Ge Y (2020) Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochem Pharmacol 182:114253","journal-title":"Biochem Pharmacol"},{"key":"1918_CR47","doi-asserted-by":"crossref","first-page":"24734","DOI":"10.18632\/aging.202361","volume":"12","author":"M Hernandez-Valladares","year":"2020","unstructured":"Hernandez-Valladares M, Aaseb\u00f8 E, Berven F, Selheim F, Bruserud \u00d8 (2020) Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. Aging 12:24734\u201324777","journal-title":"Aging"},{"key":"1918_CR48","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","volume":"29","author":"D Levitz","year":"2023","unstructured":"Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, Verma A, Feldman EJ, Goldfinger M (2023) A metabolically optimized, noncytotoxic low-dose weekly decitabine\/venetoclax in MDS and AML. Clin Cancer Res 29:2774\u20132780","journal-title":"Clin Cancer Res"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-023-01918-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-023-01918-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-023-01918-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:10:25Z","timestamp":1708387825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-023-01918-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":48,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1007\/s10495-023-01918-1","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"3 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}